Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166595 · ClinicalTrials.gov registry record · Phase 1
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
A Phase 1 study of Child Development Disorders, Pervasive, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT00166595 is a Phase 1 study of Child Development Disorders, Pervasive that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 100 participants, above the 84-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (19% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT00166595, a Phase 1 study of Child Development Disorders, Pervasive, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in children in relation to side effects and clinical response to risperidone.
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (4)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- The Ohio State University Medical Center - Columbus
Michigan
- Children's Hospital of Michigan/Wayne State University - Detroit
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166595
The ClinicalTrials.gov registry entry for NCT00166595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 4 other Child Development Disorders, Pervasive trials with a reported enrollment target (19% higher). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Child Development Disorders, Pervasive appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT00166595 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00166595 about?
NCT00166595 is a clinical study titled "Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)". The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in ch...
What is the current status of trial NCT00166595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2003-02. Estimated completion is 2005-03.
What conditions does trial NCT00166595 study?
This clinical trial studies the following conditions: Child Development Disorders, Pervasive.
What interventions are being tested in trial NCT00166595?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00166595?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00166595 being conducted?
This trial has 4 study locations across Michigan, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Child Development Disorders, Pervasive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
COMPLETED · Phase 1
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
COMPLETED · NA
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.